Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2002; 87(02): 211-217
DOI: 10.1055/s-0037-1612975
DOI: 10.1055/s-0037-1612975
Letters to the Editor
Prospective Study on Soluble Thrombomodulin and von Willebrand Factor and the Risk of Ischemic and Hemorrhagic Stroke
Further Information
Publication History
Received
30 June 2001
Accepted after resubmission
25 October 2001
Publication Date:
13 December 2017 (online)
Summary
The aim of the present study was to examine if soluble thrombomodulin (sTM) and von Willebrand factor (VWF) could predict a first-ever ischemic or hemorrhagic stroke.
This study was an incident case-referent study from within a population-based cohort in northern Sweden. Up to 1996 about 44,000 subjects had been screened and stroke cases were classified according to the WHO MONICA criteria. A first-ever stroke occurred in 108 cases. A total of 216 controls were selected from the same cohort.
This prospective study found no association with sTM or VWF and the development of a first-ever ischemic stroke (n = 87) in the logistic regression model. For the hemorrhagic stroke cases (n = 18), the multivariate logistic regression model revealed a significant negative association with sTM. When dichotomized, the upper level (>17.3 µg/L) of sTM, as compared with the lower level (<17.3 µg/L), showed one fifth of the risk for hemorrhagic stroke (OR, 0.18; CI, 0.05 to 0.69). No significant association was found for VWF. We suggest that the novel finding of an inverse relation between sTM and hemorrhagic stroke should be investigated in a larger study.
-
References
- 1 Smith FB, Lowe GD, Fowkes FG, Rumley A, Rumley AG, Donnan PT. et al. Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral arterial disease. Atherosclerosis 1993; 102 (02) 155-62.
- 2 Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?. Cardiovasc Res 1997; 34 (02) 255-65.
- 3 Blann AD, Seigneur M, Steiner M, Boisseau MR, McCollum CN. Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease. Eur J Clin Invest 1997; 27 (11) 916-21.
- 4 Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H. et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study [see comments]. Lancet 1999; 353 9166 1729-34.
- 5 Jansson JH, Nilsson TK, Johnson O. von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart 1998; 80 (04) 334-7.
- 6 Blann AD, de Romeuf C, Mazurier C, McCollum CN. Circulating von Willebrand factor antigen II in atherosclerosis: a comparison with von Willebrand factor and soluble thrombomodulin. Blood Coagul Fibrinolysis 1998; 09 (03) 261-6.
- 7 Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17 (11) 3321-5.
- 8 Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66 (05) 351-5.
- 9 Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group [see comments]. N Engl J Med 1995; 332 (10) 635-41.
- 10 Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96 (04) 1102-8.
- 11 Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ. et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1999; 100 (07) 736-42.
- 12 Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78 (04) 2249-52.
- 13 Ishii H, Nakano M, Tsubouchi J, Ishikawa T, Uchiyama H, Hiraishi S. et al. Establishment of enzyme immunoassay of human thrombomodulin in plasma and urine using monoclonal antibodies. Thromb Haemost 1990; 63 (02) 157-62.
- 14 Boffa MC. Considering cellular thrombomodulin distribution and its modulating factors can facilitate the use of plasma thrombomodulin as a reliable endothelial marker?. Haemostasis 1996; 26 Suppl 4: 233-43.
- 15 Blann AD, Amiral J, McCollum CN. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease. Eur J Haematol 1997; 59 (02) 115-20.
- 16 Jansson JH, Boman K, Brannstrom M, Nilsson TK. Increased levels of plasma thrombomodulin are associated with vascular and all-cause mortality in patients on long-term anticoagulant treatment. Eur Heart J 1996; 17 (10) 1503-5.
- 17 Jansson JH, Boman K, Brannstrom M, Nilsson TK. High concentration of thrombomodulin in plasma is associated with hemorrhage: a prospective study in patients receiving long-term anticoagulant treatment. Circulation 1997; 96 (09) 2938-43.
- 18 Weinehall L, Johnson O, Jansson JH, Boman K, Huhtasaari F, Hallmans G. et al. Perceived health modifies the effect of biomedical risk factors in the prediction of acute myocardial infarction. An incident case-control study from northern Sweden. J Intern Med 1998; 243 (02) 99-107.
- 19 Tunstall-Pedoe H. WHO MONICA Project Principal Investigators. The World Health Organization MONICA Project (Monitoring Trends and Determinants in Cardiovascular Disease): A major international collaboration. J Clin Epidemiol 1988; 41 (02) 105-14.
- 20 Stegmayr B, Asplund K. Measuring stroke in the population: quality of routine statistics in comparison with a population-based stroke registry. Neuroepidemiology 1992; 11 4-6 204-13.
- 21 Stegmayr B, Asplund K, Wester PO. Trends in incidence, case-fatality rate, and severity of stroke in northern Sweden, 1985-1991. Stroke 1994; 25 (09) 1738-45.
- 22 Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem 1982; 28 (06) 1356-8.
- 23 Amiral J, Adam M, Mimilla F, Larrivaz I, Chambrette B, Boffa MC. Design and validation of a new immunoassay for soluble forms of thrombomodulin and studies on plasma. Hybridoma 1994; 13 (03) 205-13.
- 24 Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F. et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98 (21) 2241-7.
- 25 Gill JC, Endres-Brooks J, Bauer PJ, Marks Jr WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69 (06) 1691-5.
- 26 Levy G, Ginsburg D. Getting at the variable expressivity of von Willebrand disease. Thromb Haemost 2001; 86 (01) 144-8.
- 27 Liu L, Lin Z, Shen Z. Changes of von Willebrand factor and antithrombin III levels in acute stroke: difference between thrombotic and haemorrhagic stroke. Thromb Res 1993; 72 (04) 353-8.
- 28 Fareed J, Messmore HL. Plasma thrombomodulin level as a predictor of hemorrhagic (and thrombotic) events in patients on long-term anticoagulant treatment. Circulation 1997; 96 (09) 2765-8.
- 29 Rosenberg RD, Aird WC. Vascular-bed--specific hemostasis and hypercoagulable states. N Engl J Med 1999; 340 (20) 1555-64.
- 30 Macko RF, Killewich LA, Fernandez JA, Cox DK, Gruber A, Griffin JH. Brain-specific protein C activation during carotid artery occlusion in humans. Stroke 1999; 30 (03) 542-5.
- 31 Ishii H, Salem HH, Bell CE, Laposata EA, Majerus PW. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain. Blood 1986; 67 (02) 362-5.
- 32 Wong VL, Hofman FM, Ishii H, Fisher M. Regional distribution of thrombomodulin in human brain. Brain Res 1991; 556 (01) 1-5.
- 33 Esmon CT. The endothelial cell protein C receptor. Thromb Haemost 2000; 83 (05) 639-43.
- 34 Bajzar L, Nesheim M, Morser J, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273 (05) 2792-8.
- 35 Mosnier LO, Meijers JC, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85 (01) 5-11.
- 36 Sakkinen PA, Macy EM, Callas PW, Cornell ES, Hayes TE, Kuller LH. et al. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol 1999; 149 (03) 261-7.
- 37 Bashir SA, Duffy SW, Qizilbash N. Repeat measurement of case-control data: corrections for measurement error in a study of ischaemic stroke and haemostatic factors. Int J Epidemiol 1997; 26 (01) 64-70.